KCNH2 and metabolic disease: We draw inspiration from the example of insulin-tropic sulfonylureas--glimepiride, which selectively binds to pancreatic SUR1 receptors, avoiding adverse effects on cardiovascular KATP channels.48,49 By pursuing these strategies, we can harness the therapeutic potential of KCNH2 inhibition in the management of metabolic diseases while mitigating associated safety concerns, ultimately offering new avenues for effective and safe treatment options.